JP2018505152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505152A5 JP2018505152A5 JP2017534727A JP2017534727A JP2018505152A5 JP 2018505152 A5 JP2018505152 A5 JP 2018505152A5 JP 2017534727 A JP2017534727 A JP 2017534727A JP 2017534727 A JP2017534727 A JP 2017534727A JP 2018505152 A5 JP2018505152 A5 JP 2018505152A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- peptide
- seq
- nos
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 17
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 8
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 239000000863 peptide conjugate Substances 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002131 composite material Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- 239000000562 conjugate Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000011347 resin Substances 0.000 description 22
- 229920005989 resin Polymers 0.000 description 22
- 239000000203 mixture Substances 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000006596 Alder-ene reaction Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- UJRIYYLGNDXVTA-UHFFFAOYSA-N ethenyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC=C UJRIYYLGNDXVTA-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 4
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- HCZMHWVFVZAHCR-UHFFFAOYSA-N 2-[2-(2-sulfanylethoxy)ethoxy]ethanethiol Chemical compound SCCOCCOCCS HCZMHWVFVZAHCR-UHFFFAOYSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- QTUVCTXXMOZFHS-UHFFFAOYSA-N N-(8-aminooctyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetamide Chemical compound NCCCCCCCCNC(=O)COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O QTUVCTXXMOZFHS-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 101100364827 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) ahcY gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096106P | 2014-12-23 | 2014-12-23 | |
| US62/096,106 | 2014-12-23 | ||
| PCT/IB2015/059901 WO2016103192A1 (en) | 2014-12-23 | 2015-12-22 | Amino acid and peptide conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000444A Division JP2021073199A (ja) | 2014-12-23 | 2021-01-05 | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505152A JP2018505152A (ja) | 2018-02-22 |
| JP2018505152A5 true JP2018505152A5 (enExample) | 2019-02-07 |
Family
ID=56149361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534727A Pending JP2018505152A (ja) | 2014-12-23 | 2015-12-22 | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
| JP2021000444A Pending JP2021073199A (ja) | 2014-12-23 | 2021-01-05 | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000444A Pending JP2021073199A (ja) | 2014-12-23 | 2021-01-05 | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10253062B2 (enExample) |
| EP (1) | EP3237374A4 (enExample) |
| JP (2) | JP2018505152A (enExample) |
| KR (1) | KR20170094449A (enExample) |
| CN (1) | CN107250103A (enExample) |
| AU (2) | AU2015370479B2 (enExample) |
| BR (1) | BR112017013574A2 (enExample) |
| CA (1) | CA2971677A1 (enExample) |
| IL (1) | IL252902A0 (enExample) |
| MX (1) | MX2017008406A (enExample) |
| RU (1) | RU2017126206A (enExample) |
| SG (1) | SG11201704962WA (enExample) |
| WO (1) | WO2016103192A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011150022A2 (en) * | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| EP3574922B1 (en) | 2013-04-10 | 2021-09-15 | Syndevrx, Inc. | Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity |
| CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| CA2971677A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| TW201735952A (zh) | 2016-02-26 | 2017-10-16 | 瑪格蕾特 安 布萊博 | 胺基酸及肽共軛物以及共軛過程 |
| NL2018803B1 (en) * | 2017-04-27 | 2018-11-05 | Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc | Adjuvant compounds |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0014815A3 (de) | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
| US4939240A (en) | 1983-03-04 | 1990-07-03 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
| US4918164A (en) | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| DE3813821A1 (de) | 1988-04-22 | 1989-11-02 | Hoechst Ag | Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung |
| US6074650A (en) | 1985-06-24 | 2000-06-13 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| US6024964A (en) | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| US4743543A (en) | 1985-09-09 | 1988-05-10 | Coulter Corporation | Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample |
| US4921790A (en) | 1987-04-24 | 1990-05-01 | Research Corporation | Tumor specific assay for CA125 ovarian cancer antigen |
| US5053489A (en) | 1988-01-29 | 1991-10-01 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
| US4963484A (en) | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
| US4914021A (en) | 1988-03-04 | 1990-04-03 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
| US4921789A (en) | 1988-04-20 | 1990-05-01 | New England Deaconess Hospital Corporation | Marker for colorectal carcinoma and methods of detecting the same |
| JPH02172946A (ja) | 1988-12-26 | 1990-07-04 | Shinetsu Sakusan Vinyl Kk | カルボン酸アルケニルエステルの製造方法 |
| US5110911A (en) | 1989-11-02 | 1992-05-05 | Biomira, Inc. | Human tumor-associated thomsen-friedenreich antigen |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| CA2117477C (en) | 1992-12-11 | 2001-06-12 | Peter S. Mezes | Multivalent single chain antibodies |
| AU6102494A (en) | 1993-02-05 | 1994-08-29 | Epigen, Inc. | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
| US6310180B1 (en) | 1993-06-21 | 2001-10-30 | Vanderbilt University | Method for synthesis of proteins |
| DE4331011A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik |
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| JPH08248579A (ja) | 1995-03-14 | 1996-09-27 | Mitsubishi Paper Mills Ltd | ハロゲン化銀写真感光材料及びその処理方法 |
| US5994294A (en) | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| US6251603B1 (en) | 1996-10-03 | 2001-06-26 | Ludwig Institute For Cancer Research | Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| DE69837273T2 (de) | 1997-10-08 | 2008-01-31 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen |
| US6602505B2 (en) * | 1998-04-30 | 2003-08-05 | University Of Southern California | Viral chimeras comprised of CAEV and HIV-1 genetic elements |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| PT1147117E (pt) | 1999-02-01 | 2004-10-29 | Eisai Co Ltd | Compostos adjuvantes imunologicos |
| JP4615805B2 (ja) | 1999-11-15 | 2011-01-19 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用 |
| WO2001055393A2 (en) | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| AU2001273639A1 (en) | 2000-06-26 | 2002-01-08 | Neurogen Corporation | Aryl fused substituted 4-oxy-pyridines |
| US6506875B1 (en) | 2000-09-26 | 2003-01-14 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-C molecules and uses thereof |
| GB0030067D0 (en) | 2000-12-11 | 2001-01-24 | Univ Bristol | Therapeutic agent |
| EP1229043A1 (en) | 2001-01-30 | 2002-08-07 | Cyto-Barr B.V. | Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| AU2002353485B2 (en) | 2001-12-04 | 2009-01-15 | Ben Gurion University Of The Negev Research And Development Authority | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| AU2003274463B2 (en) | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| GB0214528D0 (en) * | 2002-06-24 | 2002-08-07 | Univ Aberdeen | Materials and methods for induction of immune tolerance |
| US7569225B2 (en) | 2002-08-12 | 2009-08-04 | The Council Of The Queensland Institute Of Medical Research | Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| ES2535451T3 (es) | 2002-08-12 | 2015-05-11 | The Council Of The Queensland Institute Of Medical Research | Nuevos lipopéptidos inmunógenos que comprenden epítopos de linfocitos T auxiliares y de linfocitos T citotóxicos (CTL) |
| WO2004041849A1 (en) | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| US7491395B2 (en) | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| US20080139464A1 (en) | 2003-05-30 | 2008-06-12 | Ludwig Institute Of Cancer Research | Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof |
| US20070197541A1 (en) | 2003-07-29 | 2007-08-23 | Oyelere Adegboyega K | Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same |
| EP1666056A1 (en) | 2004-12-06 | 2006-06-07 | Bestewil Holding B.V. | Cancer vaccine vesicles |
| FR2881746B1 (fr) * | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| EP1850832B1 (en) | 2005-02-07 | 2014-12-31 | Lipotek PTY Ltd | Adjuvanting material |
| EP1861426A4 (en) | 2005-02-08 | 2008-11-12 | Queensland Inst Med Res | IMMUNOGENOUS MOLECULES |
| GB0507003D0 (en) | 2005-04-06 | 2005-05-11 | Molmed Spa | Therapeutic |
| CA2616906A1 (en) | 2005-05-12 | 2006-11-23 | Tapestry Pharmaceuticals, Inc. | Molecular constructs suitable for targeted conjugates |
| CN100548377C (zh) * | 2005-07-18 | 2009-10-14 | 曾毅 | 含经修饰后的树突状细胞的疫苗组合物 |
| EP1933834A1 (en) | 2005-10-12 | 2008-06-25 | Biolipox AB | Benzoxazoles useful in the treatment of inflammation |
| JP4824389B2 (ja) | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| EP1963358A4 (en) | 2005-12-06 | 2009-03-25 | Univ Australian | TREATMENT OF DISEASES ASSOCIATED WITH THE EPSTEIN-BARR-VIRUS |
| WO2007078879A2 (en) | 2005-12-21 | 2007-07-12 | Vaxinnate Corporation | Lipopeptide compositions and methods of use thereof |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2008021296A2 (en) | 2006-08-14 | 2008-02-21 | Thymon, L.L.C. | Compositions and methods for the treatment and prophylaxis of alzheimer's disease |
| US8309096B2 (en) | 2007-01-15 | 2012-11-13 | Glaxosmithkline Biologicals S.A. | Fusion protein |
| EP2118128B1 (en) | 2007-01-15 | 2012-11-07 | GlaxoSmithKline Biologicals SA | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 |
| EP3533461A3 (en) | 2007-03-26 | 2019-12-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Prame derived peptides and immunogenic compositions comprising these |
| WO2008151197A2 (en) | 2007-06-04 | 2008-12-11 | The Regents Of The University Of California | Tumor-derived endogenous toll-like receptor 4 ligands |
| US20110262473A1 (en) | 2008-07-07 | 2011-10-27 | The University Of Melbourne | Synthetic vaccine component |
| US20100266623A1 (en) | 2008-07-07 | 2010-10-21 | The University Of Melbourne | Synthetic, self adjuvanting vaccines |
| US20110171259A1 (en) | 2008-09-05 | 2011-07-14 | Martin Gagne | Novel Compositions and Adjuvants |
| US8436015B2 (en) | 2008-09-15 | 2013-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US8822485B2 (en) | 2009-11-23 | 2014-09-02 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| WO2011109237A2 (en) | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
| US10238734B2 (en) | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| US20130029358A1 (en) | 2010-04-01 | 2013-01-31 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
| WO2011156686A2 (en) | 2010-06-11 | 2011-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| EP2608806B1 (en) | 2010-08-25 | 2017-10-25 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | An epstein-barr-virus vaccine |
| US20140086888A1 (en) | 2010-09-01 | 2014-03-27 | Helen E. Heslop | Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc) |
| BR112013005970A2 (pt) | 2010-09-14 | 2016-07-05 | Council Scient Ind Res | imunógeno sintético, últil para gerar imunidade duradoura e proteção contra patógenos. |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| WO2012069188A1 (en) | 2010-11-24 | 2012-05-31 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V | Continuous flow processes for photoconjugation of high-molecular chemical entities |
| US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| WO2012123755A1 (en) * | 2011-03-17 | 2012-09-20 | The University Of Birmingham | Re-directed immunotherapy |
| US9309278B2 (en) | 2011-05-13 | 2016-04-12 | Nanyang Technological University | Method for modification of organic molecules |
| US20120328660A1 (en) | 2011-06-03 | 2012-12-27 | Tsuji Takemasa | Immunogenic compositions useful in provoking an integrated response to tumor antigens |
| GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
| WO2013036543A2 (en) | 2011-09-10 | 2013-03-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Molecular imaging of cancer cells in vivo |
| NL2007536C2 (en) | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
| IN2014CN02581A (enExample) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| US9056141B2 (en) | 2012-05-31 | 2015-06-16 | Synchem, Inc. | Thiol-ene click chemistry for drug conjugates |
| US9861702B2 (en) * | 2012-10-22 | 2018-01-09 | Wisconsin Alumni Research Foundation | Lipid-conjugated rhamnose for immune system recruitment and oncotherapy |
| JP6548579B2 (ja) | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| CA2971677A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| TW201735952A (zh) | 2016-02-26 | 2017-10-16 | 瑪格蕾特 安 布萊博 | 胺基酸及肽共軛物以及共軛過程 |
-
2015
- 2015-12-22 CA CA2971677A patent/CA2971677A1/en not_active Abandoned
- 2015-12-22 EP EP15872074.8A patent/EP3237374A4/en not_active Withdrawn
- 2015-12-22 RU RU2017126206A patent/RU2017126206A/ru not_active Application Discontinuation
- 2015-12-22 US US15/535,956 patent/US10253062B2/en active Active
- 2015-12-22 SG SG11201704962WA patent/SG11201704962WA/en unknown
- 2015-12-22 JP JP2017534727A patent/JP2018505152A/ja active Pending
- 2015-12-22 KR KR1020177020221A patent/KR20170094449A/ko not_active Ceased
- 2015-12-22 MX MX2017008406A patent/MX2017008406A/es unknown
- 2015-12-22 BR BR112017013574A patent/BR112017013574A2/pt not_active Application Discontinuation
- 2015-12-22 CN CN201580076680.8A patent/CN107250103A/zh active Pending
- 2015-12-22 AU AU2015370479A patent/AU2015370479B2/en not_active Ceased
- 2015-12-22 WO PCT/IB2015/059901 patent/WO2016103192A1/en not_active Ceased
-
2017
- 2017-06-14 IL IL252902A patent/IL252902A0/en unknown
-
2019
- 2019-01-18 US US16/251,136 patent/US11014960B2/en not_active Expired - Fee Related
-
2020
- 2020-10-16 AU AU2020256429A patent/AU2020256429A1/en not_active Abandoned
-
2021
- 2021-01-05 JP JP2021000444A patent/JP2021073199A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102461744B1 (ko) | 아미노 2산을 함유한 펩타이드 변형제 | |
| CN109195618A (zh) | 用于合成α4β7肽拮抗剂的方法 | |
| EP3398957B1 (en) | Method for synthesizing etelcalcetide | |
| JPS5833863B2 (ja) | サケ・カルシトニンの合成 | |
| JPWO2016140232A1 (ja) | ペプチド合成方法 | |
| TW201024316A (en) | Process for the preparation of Pramlintide | |
| CN111566123A (zh) | 胰高血糖素样肽的制备方法 | |
| JPS5962556A (ja) | 非天然アミノ酸 | |
| TW201915009A (zh) | 合成依特卡肽（Ｅｔｅｌｃａｌｃｅｔｉｄｅ）或其鹽類之方法 | |
| AU2020334993A1 (en) | Methods of making incretin analogs | |
| WO2018205401A1 (zh) | 一种普利卡那肽的制备方法 | |
| JP2009500298A5 (enExample) | ||
| US6897289B1 (en) | Peptide synthesis procedure in solid phase | |
| CN105408344B (zh) | 肽-树脂结合物及其用途 | |
| TW201109347A (en) | Producing method of thioester compound of peptide | |
| CN104177490A (zh) | 片段缩合制备醋酸鲑鱼降钙素的方法 | |
| JPWO2010016551A1 (ja) | ジベンゾフルベンの除去方法 | |
| EP3359557A1 (en) | New methods for making barusiban and its intermediates | |
| JP6010052B2 (ja) | 複数のペプチド断片をアッセンブルすることによるペプチドを調製するための方法 | |
| EP0353565A1 (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical commpositions containing them | |
| CN106749545A (zh) | Gymnopeptide a和gymnopeptide b的制备方法 | |
| JPH04243897A (ja) | 環状ｈｉｖの主要中和決定基ペプチド | |
| CN106831950A (zh) | 一种制备利那洛肽的方法 | |
| JP2010537984A (ja) | ポリペプチドおよび蛋白質の化学合成のための方法および中間体 | |
| JP2005325109A (ja) | 環状ペプチド中のジスルフィド結合の形成方法 |